Latest studies
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II Combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors
This study is testing a new combination of medicines for adults with liver cancer that has spread too widely to be removed by surgery. It's for people whose cancer has already been treated with a type of immunotherapy. Researchers want to see how well these new combinations work.
Unresectable Hepatocellular Carcinoma (HCC)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, upadacitinib, for people aged 18 and over with moderate to severe eczema (atopic dermatitis). They want to see how well it clears up skin, reduces itching, and improves quality of life over 16 weeks compared to a dummy pill.
Moderate and Severe Atopic DermatitisItaly - Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
This study is gathering important information about a rare kidney disease called atypical Hemolytic-Uremic Syndrome (aHUS). It looks at how the disease progresses and how safe new treatments like eculizumab and ravulizumab are for patients of all ages.
Atypical Hemolytic-Uremic SyndromeItaly - AuthorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
This study is testing a new weekly pill for HIV to see if it's as good as a daily pill people already take. It's for adults whose HIV is already under control. We want to check how safe and effective the new weekly treatment is.
HIV-1 InfectionItaly - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal AdenocarcinomaItaly - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesityItaly - Active not recruitingPHASE4
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
This study looks at a medicine called OM-85 to see if it can help young children, aged 6 months to 5 years, who get lots of chest infections and wheezing. We want to know if it's safe and effective at reducing how often they get ill.
Respiratory Tract InfectionsWheezing Lower Respiratory IllnessItaly - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase IB, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)
This study is testing a new medicine, crovalimab, for people with sickle cell disease who are having a pain crisis (called a vaso-occlusive episode). We want to see if it's safe, how it works in the body, and if it helps reduce pain and other problems.
Sickle Cell DiseaseItaly - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Italy - Active not recruitingPHASE2
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
This study is testing a new weekly drug called rezafungin for adults with a serious lung infection called Chronic Pulmonary Aspergillosis (CPA). It's for people who haven't found other treatments effective or can't take them. We want to see if it's safe and helps improve their health over six months.
Chronic Pulmonary AspergillosisItaly - Active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
Neoplasm MalignantRenal Cell CarcinomaHormone Receptor Positive Breast CarcinomaMetastatic Castration-resistant Prostate CancerItaly - RecruitingPHASE1, PHASE2
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This study is testing a new medicine, AZD4512, for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to past treatments. It looks at how safe and effective the medicine is, sometimes on its own, and sometimes with other cancer drugs.
B-cell Non-Hodgkin LymphomaItaly - RecruitingPHASE2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
This study is testing a new medicine, GSK4532990, for people aged 18-70 with liver damage caused by alcohol. We want to see if it's safe and if it helps the liver. Some people will get the medicine, others a dummy pill.
Liver Diseases, AlcoholicItaly - RecruitingPHASE2
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
This study is testing a new medicine, ensifentrine, for people with a lung condition called non-cystic fibrosis bronchiectasis. We want to see if it helps reduce flare-ups, improve breathing, and make people feel better, compared to a dummy medicine.
Non-cystic Fibrosis BronchiectasisItaly - AuthorisedPhase II and Phase III (Integrated)
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
This study looks at new ways to treat a type of skin cancer in the eye that has spread (metastatic uveal melanoma). It compares two drug combinations, RP2 with Nivolumab, against Ipilimumab with Nivolumab, to see which is safer and more effective.
metastatic uveal melanomaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
This study looks at a new drug combination for Primary Biliary Cholangitis (PBC). It checks if mixing two existing medicines, Obeticholic Acid and Bezafibrate, helps liver health over a long time. Researchers want to see how safe and effective this combination is for patients.
Primary Biliary Cholangitis (PBC)Italy - AuthorisedTherapeutic exploratory (Phase II)
A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases
This study looks at new ways to treat advanced melanoma, a type of skin cancer. It combines a standard cancer drug, pembrolizumab, with injections directly into the cancer. Researchers want to see if these new combinations can shrink tumours in people whose cancer hasn’t responded well to previous treatments.
Italy - RecruitingPHASE1
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
This study is testing a new experimental medicine, CDR404, for hard-to-treat solid cancers that have a specific marker called MAGE-A4. It's the first time CDR404 is being used in people, and doctors want to see if it's safe and if it can help fight the cancer.
Select Advanced Solid TumorsItaly - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaItaly - RecruitingPHASE3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
This study is testing a new medicine, volrustomig, for people with a type of head and neck cancer that hasn't spread and wasn't removed by surgery. It aims to see if volrustomig helps prevent the cancer from coming back after standard treatment like chemotherapy and radiotherapy.
Locally Advanced Head and Neck Squamous Cell CarcinomaItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
This study is testing a new medicine, AOC 1020, for people with Facioscapulohumeral Muscular Dystrophy (FSHD). We want to see if it's safe, how the body handles it, and if it helps. This is one of the first times this medicine will be given to people.
Facioscapulohumeral muscular dystrophy (FSHD)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking at a new medicine called Vyvgart for people with Thyroid Eye Disease. It aims to see if the medicine can help reduce bulging eyes and improve eye health, compared to a dummy medicine, over 24 weeks.
Thyroid Eye Disease (TED)Italy - Enrolling by invitationNA
Optical Coherence Tomography in Acute Vessel Evaluation
This study compares two ways to help people having a heart attack: one uses standard X-rays, the other uses a special camera called OCT. We want to see if the OCT camera leads to better results for patients.
Ischemic Heart DiseaseIschemic Coronary Artery DiseaseACS (Acute Coronary Syndrome)Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma: a randomized phase II study (Ravina)
This study looks at a new drug, xevinapant, given with radiotherapy for older patients with advanced head and neck cancer. We want to see if this combination helps more people live longer without their cancer coming back. It's a Phase II study, meaning we're testing its effectiveness and safety.
Squamous cell carcinoma of head and neckItaly - AuthorisedTherapeutic exploratory (Phase II)
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
This study is looking at a new drug called Cabozantinib for a type of lung cancer called non-small cell lung cancer (NSCLC). It's for people whose cancer has specific genetic changes related to a protein called MET. Researchers want to see how well the drug shrinks tumours.
Non small-cell lung cancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)
This study is looking into a new medicine called SerpinPC for severe haemophilia A or B. It wants to see if SerpinPC can reduce bleeding in adults with these conditions, especially those who currently treat bleeds as they happen. Researchers will also check how safe the new medicine is.
Severe Hemophilia A or Moderately Severe to Severe Hemophilia BItaly - Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
This study is gathering information on a rare genetic condition called LAL Deficiency. It aims to understand the disease better and improve care for affected individuals, from babies to adults. It's a worldwide effort to collect health data over time.
Lysosomal Acid Lipase DeficiencyCholesterol Ester Storage DiseaseWolman DiseaseAcid Cholesteryl Ester Hydrolase Deficiency, Type 2Italy - AuthorisedTherapeutic exploratory (Phase II)
Evaluation of the Pharmacokinetics of Subcutaneous Administration of Piperacillin/Tazobactam: An Open-Label, Multicentric, Non-Inferiority Randomized Clinical Trial (STUPITA01)
This study is testing a new way to give an antibiotic called piperacillin/tazobactam for infections. Instead of only giving it through a drip, researchers want to see if giving it as an injection under the skin works just as well and is safe for adults.
Infectious diseaseItaly - RecruitingPHASE2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Imeroprubart, for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyItaly - Active not recruitingPHASE2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
This study looks at a new drug, tulisokibart, for people with a lung condition called interstitial lung disease (ILD) linked to scleroderma. We want to see if it's safe and helps improve the condition.
Diffuse Cutaneous Systemic SclerosisInterstitial Lung DiseaseItaly - RecruitingPHASE2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
This study looks at new treatments for stomach or food pipe cancer that can be removed by surgery. It aims to see how safe and effective these new drugs or drug combinations are before and after the operation.
Gastroesophageal AdenocarcinomaItaly - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab
This study is looking at a new treatment called teprotumumab for Thyroid Eye Disease. It aims to safely see if different lengths of taking the medicine affect how well it works and if people need further treatment later.
Thyroid Eye DiseaseItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment-naïve Pediatric Participants with Infantile-Onset Pompe Disease (IOPD)
This study is testing a new medicine, Nexviadyme, for babies with a rare genetic condition called Pompe disease. It aims to see if the medicine helps them breathe better and grow, and if it's safe, especially for those who haven't tried other treatments.
Glycogen storage disease type IIItaly - Active not recruitingPHASE3
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
This study is testing a new medicine, selumetinib, for adults with a condition called Neurofibromatosis Type 1 (NF1). It focuses on people who have painful, non-removable growths called plexiform neurofibromas. We want to see if this medicine can help reduce symptoms and safely shrink these growths.
Neurofibromatosis 1Plexiform Neurofibroma (PN)Italy - Active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
Muscle-invasive Bladder CancerItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking into a new treatment called Efgartigimod for Thyroid Eye Disease (TED). Researchers want to see how well it works, if it's safe, and if it causes any side effects. It's a big study involving many people, with some receiving the new drug and others a dummy treatment.
Thyroid Eye Disease (TED)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Obesity, Chronic Kidney disease, Type 2 Diabetes, Cardiovascular Diseases, Overweight or Obesity, OverweightItaly - Active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
Urinary Bladder NeoplasmsMuscle-Invasive Bladder CancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
This study is testing a new medicine, MK-2060, to see if it can stop blood clots forming in special tubes (grafts) used for kidney dialysis. We want to know if it's safe and if it works better than a dummy medicine (placebo) for people with serious kidney disease.
Prevention of arteriovenous graft thrombosisItaly - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory BCell Non Hodgkin Lymphoma (ZUMA-4)
This study is testing a new treatment called Tecartus for children and teenagers with certain types of blood cancer (leukaemia and lymphoma) that have come back after treatment. We want to see how safe it is and how well it works to help patients get better.
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)Italy - Active not recruitingPHASE3
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
This study is looking at a new medicine called efanesoctocog alfa (BIVV001) for people with haemophilia A. It aims to see if it's safe and effective over a long time in preventing and treating bleeds, improving joint health and quality of life.
Hemophilia AItaly - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
Systemic Juvenile Idiopathic ArthritisItaly - AuthorisedPhase I and Phase II (Integrated)- Other
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma.
This study is testing a new antibody treatment, L19TNF, along with standard brain cancer medication, temozolomide. It aims to see if combining them is safe and helps people with a type of brain tumour called glioblastoma live longer and feel better.
GlioblastomaItaly - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisItaly - Active not recruitingPHASE2
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
This study looks at how safe and well a medicine called Miransertib is for children and adults with certain growth conditions (PROS or Proteus Syndrome). It's for people already in other Miransertib studies or about to start, exploring long-term effects.
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)Italy - AuthorisedPhase II and Phase III (Integrated)
An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition
This study is for children aged 3-18 with a type of brain tumour called medulloblastoma. It looks at different ways to treat the tumour, including various chemotherapy drugs, to find the most effective and safest options for different types of medulloblastoma, aiming to improve chances of recovery and quality of life.
MedulloblastomaItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
This study is looking at a new combination of two medicines, Lenvatinib and KEYTRUDA, for adults with a type of kidney cancer called non-clear cell renal cell carcinoma (nccRCC). It’s in an early stage of testing to see how well patients respond to the treatment.
Non-clear Cell Renal Cell CarcinomaItaly - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
This study is testing a new medicine, GB-0895, for adults with severe asthma that isn't well controlled by current treatments. We want to see if it can reduce severe asthma attacks and improve breathing and quality of life over 52 weeks, compared to a dummy medicine.
Severe uncontrolled asthmaItaly - Active not recruitingPHASE3
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
This study looks at a new gene therapy, OTL-203, for children with Hurler Syndrome (MPS-IH). It compares this new treatment to the standard stem cell transplant to see which works better and is safer for these young patients.
MPS-IH (Hurler Syndrome)Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
This study is testing a new combination of medicines for people with a type of breast cancer called triple-negative breast cancer that has spread or can't be removed with surgery. It aims to see if the new combination can help people live longer without their cancer getting worse.
Triple-Negative Breast Cancer (TNBC)Italy